We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Edesa Biotech, Inc.
Health Care · Biotechnology
Structural - clinical-stage microcap (~$18M cap, no revenue) with a single high-conviction asset: EB05, an anti-TLR4 monoclonal antibody. Phase 2 ARDS trial showed 68% reduction in 28-day mortality in mechanically-ventilated patients (n=58).
DoD partnership funds the Phase 3 ARDS readout - non-dilutive capital plus regulatory credibility.
Bull - (1) ARDS has no approved drug; EB05 holds FDA Fast Track + DoD funding for Phase 3; (2) TLR4 mechanism extends across indications (urticaria Phase 2 readout near-term); (3) <$20M cap on a Phase 3 asset = asymmetric optionality if data prints; (4) cash runway extended by DoD non-dilutive grants; (5) sub-3M float post-2024 reverse split limits supply.
Bear - (1) single-asset binary - EB05 failure ends the thesis; (2) microcap biotech dilution risk (frequent ATMs / registered directs); (3) ARDS Phase 2 mortality signal on small n=58 historically de-risks poorly in Phase 3; (4) Nasdaq listing compliance pressure (sub-$1 stretches historically); (5) zero analyst coverage, illiquid tape - execution on any exit is the trade.
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for EDSA - only listicles and opinion pieces, which we filter out by default. See everything anyway.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.